Zentek Ltd. filings document current-report disclosures for a Canadian issuer commercializing graphene-enabled and advanced material technologies. The company’s Form 6-K reports include exhibits on ZenGUARD™ enhanced air filters, Health Canada regulatory classification, commercialization activity and intellectual-property-based product platforms.
Regulatory filings also document Albany Graphite Project work through technical, environmental, social and economic-study disclosures, including high-purity graphite market positioning and critical-minerals analysis. Other filing subjects include Triera Biosciences contracts and aptamer-platform development, material agreements, shareholder voting matters, capital-structure disclosure, governance matters and operating and financial results.
Zentek Ltd. filed a report highlighting a strategic reset described in a new shareholder letter. The company is narrowing its efforts to three core platforms: Albany Graphite, ZenGUARD, and Triera, each managed against defined milestones, capital criteria, and a 24‑month roadmap.
Zentek is pausing or winding down non-core initiatives and is reducing its cost base through workforce and facility optimization and tighter corporate spending controls. Future capital raises will be tied to specific milestones. As part of the reset, Chief Science Officer Colin van der Kuur has departed, with responsibilities redistributed across the existing technical leadership team.
The company also plans clearer segment-level financial disclosure, milestone tracking, and updated transparency standards while aligning research and development with the three core platforms.
Zentek Ltd. filed a Form 6-K as a foreign private issuer, signed by its Chief Financial Officer, to furnish a new corporate update. The filing attaches a press release dated December 17, 2025, describing that Zentek’s subsidiary Albany Graphite Corp. achieved near-theoretical anode performance in independent battery suitability testing. This suggests the company is highlighting technical progress related to the potential use of its graphite materials in battery applications, though specific performance metrics or commercial impacts are not detailed in this excerpt.
Zentek Ltd. filed a Form 6-K as a foreign private issuer for November 2025. The report, signed by Chief Financial Officer Wendy Ford, primarily furnishes an exhibit containing a press release dated November 25, 2025, in which Zentek announces the appointment of Mohammed Jiwan as Chief Executive Officer. This filing formally notifies investors of the leadership change through the U.S. securities reporting system.
Zentek Ltd. filed a Form 6-K as a foreign private issuer, signed by its Chief Financial Officer, Wendy Ford. The filing notes that an exhibit is attached: a press release dated November 21, 2025, titled "Zentek Receives CRA Notice of Reassessment for 2019." This indicates the company has received a tax reassessment notice from the Canada Revenue Agency relating to its 2019 tax year, and is informing investors through the attached press release.
Zentek Ltd. furnished a Form 6-K providing investors with its latest interim reporting package for the three months ended September 30, 2025. The submission makes the company’s unaudited condensed interim consolidated financial statements and accompanying management discussion and analysis available, along with CEO and CFO certification of those interim filings dated November 13, 2025. These documents are also incorporated by reference into Zentek’s existing Form F-3 shelf registration statement, meaning the interim information now formally forms part of that registration framework unless later superseded.
Zentek Ltd. submitted a Form 6-K for November 2025 that mainly forwards a press release about a new product and licensing arrangement. The exhibit notes that Zentek has developed a new graphite gel-based fire-retardant product and entered into an exclusive licence with Altek Advanced Materials Inc. for the United States market. This filing formally records that product development and exclusive U.S. licensing step for investors.
Zentek Ltd. submitted a Form 6-K as a foreign private issuer for September 2025. The filing is signed by Chief Financial Officer Wendy Ford on behalf of the company. It furnishes two exhibits: a report of voting results dated September 25, 2025 and a press release dated the same day announcing the voting results of Zentek's annual and special meeting. These materials provide details on how shareholders voted on the matters presented at that meeting.
Zentek Ltd. filed a Form 6-K as a foreign private issuer. The filing mainly serves as a cover to furnish an attached press release as an exhibit.
The exhibit, dated September 18, 2025, provides a preliminary update on Zentek’s influenza countermeasure candidate developed using its multivalent aptamer technology against H1N1 seasonal influenza.